"BioSante, the original developer of Bio-T-Gel, estimates the market for male testosterone products is more than $1.2 billion in the U.S., where hypogonadism affects as many as 5 million men. BioSante, of Lincolnshire, Illinois, licensed the gel to Teva, the world’s largest generic-drug maker, and will receive milestone payments and royalties when the drug is commercialized."
The price of BPAX hit a low of 0.68 (our original price alert on Jan. 22 here http://chartsbyoriginalnewt.blogspot.com/2012/01/bpax-068-short-term-play-on-chart-and.html )Tues. bouncing off the lower trend line of the 2 month channel, as investors were waiting on FDA decision and closed the regular trading hours at 0.76, after hours trading saw an increase in price of 0.35 on 4.66 mil shares traded.
No comments:
Post a Comment